Novartis admitted the email broke several rules set out in the U.K. marketing code. In a long response to the PMCPA, the ...

Pluvicto demonstrated positive results in patients with PSMA-positive metastatic hormone-sensitive prostate cancer.

As Merck & Co., Bristol Myers Squibb and Pfizer have hopped on the PD-(L)1xVEGF bispecific bandwagon, the question becomes ...

Novartis said on Monday that its targeted radiotherapy Pluvicto was shown to slow progression of a certain type of prostate ...

Novartis is hoping that Scemblix (asciminib) will become the physician’s first choice of therapy for chronic myeloid ...

Novartis’ $1.7 billion Regulus Therapeutics buyout last month came after a hard-fought battle in which the Swiss pharma and ...

A ctDNA-guided approach can help identify when patients with HR-positive advanced breast cancer are developing an ESR1 ...

The mental health and wellbeing of our people is vitally important. It is a natural extension of our company’s purpose to discover new ways to improve and extend people’s lives. Our ambition at ...

Novartis Pluvicto demonstrates statistically significant and clinically meaningful rPFS benefit in patients with PSMA-positive mHSPC: Basel Tuesday, June 3, 2025, 12:00 Hrs [IST] ...

Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling ...

Swiss pharma giant Novartis is re-entering the booming field of ageing research. It wants to develop a blockbuster drug in ...

In the first quarter of 2025, the clinic supported over 11 000 patients, with the new equipment significantly reducing ...